Radionuclides trip portable security detectors
Nuclear medicine physicians should take not only a patient’s history, but also his or her “future.” Patients who travel after a diagnostic or therapeutic nuclear medicine procedure can accidentally trip alarms designed to catch terrorists smuggling radioactive material.
Nuclear medicine physicians should take not only a patient's history, but also his or her "future." Patients who travel after a diagnostic or therapeutic nuclear medicine procedure can accidentally trip alarms designed to catch terrorists smuggling radioactive material.
Patients can trigger radiation detectors up to three months after the administration of some nuclear therapies, according to a study presented at the 2004 RSNA meeting.
Dr. Lionel Zuckier and colleagues at the New Jersey University School of Medicine and Dentistry assessed the potential duration of radionuclides in the body by analyzing their sensitivity to detectors used by the Department of Homeland Security.
Using five different portable detectors, the researchers tested seven substances: thallium-201, technetium-99m, gallium-67, iodine-123, iodine-131, indium-111, and F-18 FDG.
They found that I-131 (including Bexxar, the non-Hodgkin's lymphoma treatment) may trigger an alarm up to 95 days postadministration. Detectable traces of the other radionuclides remain in the system for varying lengths of time:
- up to 30 days: Ga-67 and Tl-201
- up to 17 days: In-111
- up to three days: Tc-99m and I-123
- less than 24 hours: F-18 FDG
All five detectors in the experiment exhibited similar sensitivity.
While this is not a new problem (in 1986 two nuclear medicine patients set off detectors in the White House), it may become a more commonplace occurrence as portable radiation monitors proliferate and the number of nuclear medicine scans increases, said Zuckier, a professor of radiology at the New Jersey university.
The number of portable devices in use in the U.S. could be as high as 10,000, according to DHS figures. The number of diagnostic and therapeutic nuclear medicine procedures in 2002 was close to 20 million and increasing nearly 10% annually, according to figures from the Society of Nuclear Medicine.
One man a few years ago set off an alarm in a tunnel while on a bus ride from New York to Atlantic City. He had ignored warnings from his physician regarding travel restrictions.
The SNM recommends that physicians give patients a letter detailing the procedure and its date, the radionuclide and its half-life, and 24-hour contact information.
For more information from the Diagnostic Imaging archives:
Federal agency adds x-rays to carcinogen warning list
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
